What's Going On With G1 Therapeutics Stock?

G1 Therapeutics, Inc. GTHX shares are trading higher Thursday amid M&A blog speculation of a takeover offer. 

What To Know:

According to a report from Seeking Alpha, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics.  According to the report, one offer from TerSera is rumored to have a contingent value right which could value the company at between $12 and $14 per share.

G1 Therapeutics shares are climbing on heavy trading volume as investors digest the rumors of a possible takeover offer. According to data from Benzinga Pro, more than 25.4 million shares have already been traded in the session, compared to the stock’s 100-day average of 1.136 million shares.

Needham analyst Gil Blum has a Buy rating and $12 price target on G1 Therapeutics, and HC Wainwright & Co. recently maintained its Buy rating and $9 price target on the stock.

Related News: What's Going On With Affirm Stock After Earnings? 

GTHX Stock Prediction 2024:

Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.

Shares of G1 Therapeutics have an average 1-year price target of $10.17, representing an expected upside of 75.65%.

Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on G1 Therapeutics, while 6 analysts have bullish ratings. The street high price target from Needham is $12, while the street low from Wedbush is $4.

GTHX Price Action: According to Benzinga Pro, G1 Therapeutics shares are up 17.85% at $5.06 at the time of publication Thursday.

Image: james-yarema from Unsplash